A Stability Indicating Method was Developed and Validation for the Estimation of Carbamazepine in Bulk and Tablet Dosage form by UV-Spectroscopic Techniques

Abstract

Carbamazepine is an anticonvulsant. It works by decreasing nerve impulses that cause seizures and nerve pain, such as trigeminal neuralgia and diabetic neuropathy. It is well known that contemporary pharmaceutical analysis establishes robust, sensitive, economic, stability-indicating analytical procedures. The current study aimed to develop and assess UV-spectrophotometric (zero order, first order, second order, area under the curve) methods for estimating carbamazepine in its pharmaceutical dosage form. Method A is a simple zero-order spectrophotometric method for determining carbamazepine at 285 nm, and the correlation coefficient in the linearity study was found to be 0.9976, LOD, and LOQ are 0.45 and 1.48 µg/ml. Method B is a first-order spectrophotometric method for determining carbamazepine at 269 nm, and the correlation coefficient in the linearity study was found to be 0.9944, LOD, and LOQ are 0.29 and 0.96 µg/ml. Method C is a second-order spectrophotometric method for determining carbamazepine at 254 nm, and the correlation coefficient in the linearity study was found to be 1.00, LOD, and LOQ are 0.62 and 2.04 µg/ml. Method D is an area under the curve spectrophotometric method for determining carbamazepine at 266 to 300 nm, and the correlation coefficient in the linearity study was found to be 0.9975, LOD, and LOQ are 0.14 and 0.46 µg/ml. All developed methods demonstrated good repeatability and recovery with %RSD < 2. Studies on stress degradation show that oxidation and acid degradation mostly impact carbamazepine solutions.
 Keywords: Carbamazepine, UV-spectrophotometric, Tegrital, Degradation study.